Empowered Patient Podcast

Martin Brenner, CEO and Chief Scientific Officer of iBio, is focused on the untapped potential of therapeutic antibodies for obesity and cardiometabolic diseases. Leveraging AI and machine learning, iBio is streamlining the antibody discovery and optimization process and addressing the need for more complex antibody mechanisms of action. Their lead candidate, iBio 600, is an anti-myostatin antibody designed to address the side effects of muscle mass and bone density loss associated with current GLP-1 therapies. Martin explains, "We can separate this into multiple areas. First of all, there's a predictive model that suggests that there are 5,000 different targets related to disease out there. So, there are 5,000 different possibilities to make medicines. All of the currently approved antibodies target only 92 targets. Even worse, 40% of approved antibodies only target about 10. So you can imagine there's a huge untapped potential of novel targets for which antibodies could be used. The problem is that the tec